Recombinant Canine VEGF Protein, CF

Formulations:
Catalog # Availability Size / Price Qty
1603-CV-010/CF
Product Details
Citations (5)
FAQs
Reviews

Recombinant Canine VEGF Protein, CF Summary

Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is 1.5-7.5 ng/mL.
Source
E. coli-derived canine VEGF protein
Pro28-Arg190
Accession #
N-terminal Sequence
Analysis
Pro28
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
19 kDa (monomer)

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1603-CV/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

1603-CV

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues. In human, at least eight alternately spliced isoforms of VEGF ranging from 206 amino acids (aa) to 121 aa in length are known. Three isoforms, VEGF188, VEGF182, and VEGF164, have been identified in canine. Canine VEGF164 shares 91%, 90%, and 98% aa sequence identity with the rat, mouse, and feline homologs, respectively. Two type I transmembrane receptor tyrosine kinases, VEGF R1 and VEGF R2, that bind VEGF with high affinity, have been identified. Neuropilin-1, a receptor for semaphorin, also binds VEGF and acts as a co-receptor to enhance the affinity between VEGF and VEGF R2. Neuropilin-1 alone can also mediate VEGF-induced endothelial cell migration. VEGF regulates cell proliferation, migration, and survival of endothelial cells. These functions are partially mediated through the induction of nitric oxide, prostacyclin, and metalloproteinases. Together with angiopoietins or other vascular-specific growth factors, VEGF plays a separate but complementary role in angiogenesis and vasculogenesis (1 - 7).

References
  1. JingJing, L. et al. (2000) Mol. Cell Biochem. 214:23.
  2. Scheidegger, P. et al. (1999) Biol. Chem. 380:1449.
  3. Thurston, G. (2002) J. Anat. 200:575.
  4. Zachary, I. and Gliki, G. (2001) Cardiovasc. Res. 49:568.
  5. Chevalier, S. (2002) Mol. Cell Endocrinol.189:169.
  6. Robinson, C.J. and Stringer, S.E. (2001) J. Cell. Sci. 114:853.
  7. Wang, L. et al. (2003) J. Biol. Chem. 278:48848.
Long Name
Vascular Endothelial Growth Factor
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names
MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Citations for Recombinant Canine VEGF Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

  1. In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor
    Authors: LM Muellerlei, B Buxbaum, B Nell, DA Fux
    Res. Vet. Sci., 2019;124(0):233-238.
    Species: Canine
    Sample Types: Recombinant Protein
    Applications: ELISA
  2. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
    Authors: Ozelo M, Vidal B, Brown C, Notley C, Hegadorn C, Webster S, Harpell L, Ahlin J, Winterborn A, Handforth J, Arruda V, Hough C, Lillicrap D
    Blood, 2014;123(26):4045-53.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
    Authors: Kamstock D, Elmslie R, Thamm D
    Cancer Immunol. Immunother., 2007;56(8):1299-309.
    Species: Canine
    Sample Types: Plasma
    Applications: ELISA (Capture)
  4. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
    Authors: Rebuzzi L, Willmann M, Sonneck K
    Vet. Immunol. Immunopathol., 2007;115(3):320-33.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  5. A functional comparison of canine and murine bone marrow derived cultured mast cells.
    Authors: Lin TY, London CA,
    Vet. Immunol. Immunopathol., 2006;114(3):320-34.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Canine VEGF Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Canine VEGF Protein, CF and earn rewards!

Have you used Recombinant Canine VEGF Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review